A phase 1 clinical trial has shown that Juventas Therapeutics‘ regenerative medicine therapy provides clinical benefit to heart failure patients.
Phase 1 trials generally focus on safety, so the indication of clinical benefit is an encouraging sign for Cleveland-based Juventas. “We are excited to see strong signs of efficacy across multiple clinical parameters,” CEO Rahul Aras said.
The company’s technology, JVS-100, works by recruiting stem cells from the bone marrow to create new blood vessels and prevent ongoing cell death at the site of a patient’s injury.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Four months after treatment, heart failure patients involved in the study showed improvements in their performance in a walking test, as well as better scores on the Minnesota Living with Heart Failure Questionnaire, according to a statement from the company.
Juventas recently presented data from the 17-patient trial at the annual meeting of the American Society of Gene & Cell Therapy.
Juventas has already received the go-ahead from the U.S. Food and Drug Administration to begin a phase 2 trial with critical limb ischemia patients, which it expects to start later this year. The company also hopes to begin a phase 2 study of heart failure patients by early next year year.
Heart failure affects approximately 5 million Americans.
